Protagenic Therapeutics Total Liabilities
Protagenic Therapeutics total liabilities. Based on the latest financial reports, Protagenic Therapeutics (PTIX) has total liabilities worth $6.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Protagenic Therapeutics liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Protagenic Therapeutics (1995–2025)
Total liabilities of Protagenic Therapeutics from 1995 to 2025. This chart illustrates how Protagenic Therapeutics's total liabilities have evolved over time, based on quarterly financial data.
Protagenic Therapeutics Competitors by Total Liabilities
The table below lists competitors of Protagenic Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Castings PLC
LSE:CGS
|
UK | GBX40.76 Million |
|
Goldex Resources Corp
V:GDX
|
Canada | CA$1.98 Million |
|
Reneuco Berhad
KLSE:7130
|
Malaysia | RM469.23 Million |
|
Cho Thavee Public Company Limited
BK:CHO
|
Thailand | ฿2.53 Billion |
|
CardioComm Solutions Inc.
V:EKG
|
Canada | CA$823.97K |
|
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
|
India | Rs54.63 Million |
|
Ausmon Resources Ltd
AU:AOA
|
Australia | AU$1.56 Million |
|
Moab Minerals Ltd
AU:MOM
|
Australia | AU$2.34 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Protagenic Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Protagenic Therapeutics.
Liquidity & Leverage Metrics
Protagenic Therapeutics Total Liabilities Ratios Explained
Protagenic Therapeutics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagenic Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagenic Therapeutics (1995–2025)
The table below shows the annual total liabilities of Protagenic Therapeutics from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.82 Million | +623.81% |
| 2024-12-31 | $942.76K | +43.88% |
| 2023-12-31 | $655.25K | -41.49% |
| 2022-12-31 | $1.12 Million | +0.17% |
| 2021-12-31 | $1.12 Million | -44.90% |
| 2020-12-31 | $2.03 Million | +37.41% |
| 2019-12-31 | $1.48 Million | +62.67% |
| 2018-12-31 | $907.77K | +61.61% |
| 2017-12-31 | $561.69K | -17.98% |
| 2016-12-31 | $684.86K | -2.72% |
| 2015-12-31 | $704.00K | +11.75% |
| 2015-06-30 | $630.00K | +99.37% |
| 2014-12-31 | $316.00K | 0.00% |
| 2013-12-31 | $316.00K | -98.26% |
| 2012-12-31 | $18.18 Million | +62.76% |
| 2010-12-31 | $11.17 Million | -41.98% |
| 2009-12-31 | $19.25 Million | -20.17% |
| 2008-12-31 | $24.11 Million | +239.73% |
| 2007-12-31 | $7.10 Million | +66.19% |
| 2006-12-31 | $4.27 Million | +4421.01% |
| 2005-12-31 | $94.47K | -97.76% |
| 2004-12-31 | $4.21 Million | -51.88% |
| 2003-12-31 | $8.76 Million | +1.21% |
| 2002-12-31 | $8.65 Million | -10.83% |
| 2001-12-31 | $9.71 Million | +7.12% |
| 2000-12-31 | $9.06 Million | -6.18% |
| 1999-12-31 | $9.66 Million | +28.28% |
| 1998-12-31 | $7.53 Million | +204.82% |
| 1997-12-31 | $2.47 Million | -55.33% |
| 1996-12-31 | $5.53 Million | +54.90% |
| 1995-12-31 | $3.57 Million | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.